RxDoctor Payments Data

Alexandra Wright, PA

Physician Assistant · Asheville, NCNPI 1619674439

Payments from drug & device makers

$2,251in general payments, 2019–2025

Across 112 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$553
  • Harmony Biosciences LLC$390
  • Galderma Laboratories, L.p.$333
  • Sun Pharmaceutical Industries Inc.$318
  • Johnson & Johnson$188
  • Lilly USA, LLC$94
  • plus $376 from 13 others

What the payments were for

  • Food & beverage$2,10093%
  • Education$1527%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,251 in reported general payments places this provider in the 80th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$8,001
Medicare patients
20
Services billed
771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$27,498
MounjaroTirzepatide22$24,033
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,653
ProgesteroneProgesterone, Micronized31$1,093
Albuterol Sulfate HfaAlbuterol Sulfate26$612
Duloxetine Hcl18$563
Ketoconazole27$442
Hydroxyzine Hcl30$416
Levothyroxine Sodium65$399
Ondansetron OdtOndansetron23$359
Omeprazole22$309
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$288
Buspirone Hcl21$286
Fluticasone Propionate27$270
Zolpidem Tartrate26$246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$23$27,49822 claims
Lilly USA, LLCMounjaro$94$24,03322 claims
GSKTrelegy Ellipta$21$9,65314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →